Ferriprox®
-
Product Information
Scientific name: Deferiprone
Brand name: Ferriprox
RESPONSIBLE: Chiesi Farmaceutici S.p.A. -
Clinical Trial/Study Information
Trial Name: N/A
Code: N/A
Phase: N/A
Eligible patient diagnosis: N/A
No. of Patients enrolled: N/A
Study Sites: N/A Sites per countryAnticipated completion date: N/A
Scope of the Study / Aim: N/A -
Regulatory Information
Status: Authorised
Update: 30 September 2025
No update.
Update: 30 June 2025
Data presented at the 30th EHA Annual Congress (12 – 15 June) in Milan, Italy showed the real-world safety profile for deferiprone twice-a-day (BID) from 425 patients, children and adults, including 133 with thalassaemia and 197 with SCD, in the USA. The most frequent adverse events are shown in the table below:
Update: 31 March 2025
No update available.
Update: 19 December 2024
Ferriprox® extended-release (twice daily) tablets for patients with thalassaemia is approved in USA, Canada, UAE, Oman, Bahrain, Indonesia, Malaysia and Brazil.
Source: Company correspondence
Update: 30 September 2024
No update available.
Update: 30 June 2024
No update available.
Update: 31 March 2024
No update available.
Update: 20 December 2023
No update available.
Update: 30 September 2023
No update available.
Update: 30 June 2023
- Health Canada has approved Ferriprox® extended-release (twice daily) tablets (1,000mg) for patients with transfusional iron overload due to thalassemia, when current chelation therapy is inadequate, or SCD or other anaemias.
Ferriprox® was previously approved in Canada for the treatment of patients with transfusional iron overload due to thalassemia when current chelation therapy is inadequate in 2015, and subsequently approved for the treatment of iron overload in patients with SCD or other anemias in 2021.
Update: 31 March 2023
No update available.
